6 unknown, 4 completed, 3 terminated, 1 suspended. 9 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Unknown 4, Completed 3, Terminated 2 |
| Phase 1 | 5 | Completed 2, Suspended 1, Terminated 1, Unknown 1 |
Follow HER-2 Gene Amplification: new trials by email Literature Review of HER-2 Gene Amplification trials Research Report on HER-2 Gene Amplification
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors ORM-5029 - HER2-positive Breast Cancer, HER-2 Protein Overexpression | Phase 1 | Terminated | Orum Therapeutics USA, Inc. | 25 | 2022-10-03 | 2025-07-04 |
| A Study of Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma Trastuzumab - Carcinoma, Transitional Cell, HER-2 Gene Amplification | Phase 2 | Unknown | Chinese Academy of Medical Sciences | 30 | 2022-03-10 | 2022-04-08 |
| Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Esophageal Squamous Cell Carcinoma Patients Trastuzumab - Esophageal Squamous Cell Carcinoma, HER-2 Protein Overexpression | Phase 2 | Unknown | Morten Mau-Sørensen | 24 | 2022-02-04 | 2022-08-12 |
| CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors CT-0508, Pembrolizumab - HER2-positive, Adenocarcinoma | Phase 1 | Unknown | Carisma Therapeutics Inc | 48 | 2021-02-02 | 2024-12-18 |
| Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors chimeric antigen receptor (CAR) T cell therapy - HER-2 Gene Amplification, HER2-positive Gastric Cancer | Phase 1 | Suspended | Bellicum Pharmaceuticals | 220 | 2020-12-07 | 2023-04-20 |
| Trastuzumab Biosimilar (Samfenet®) Plus Treatment of Physician's Choice (TPC) in Patients With HER2-positive Solid Tumor Trastuzumab biosimilar, Gemcitabine Hydrochloride, Irinotecan Hydrochloride - HER-2 Protein Overexpression, HER-2 Gene Amplification | Phase 2 | Unknown | Jin-Hee Ahn | 42 | 2019-12-30 | 2020-01-02 |
| The Basket Study of Pyrotinib Maleate for HER2-Postive Solid Tumor Pyrotinib - Solid Tumor, HER2 Gene Mutation | Phase 2 | Unknown | Tianjin Medical University Second Hospital | 100 | 2019-12-01 | 2019-11-27 |
| Trastuzumab in HER2-positive Biliary Tract Cancer Trastuzumab - Cholangiocarcinoma, Biliary Tract Cancer | Phase 2 | Completed | Changhoon Yoo | 4 | 2019-06-01 | 2021-01-05 |
| Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas Oxaliplatin, Leucovorin, 5 fluorouracil - Gastric Adenocarcinoma, Esophageal Adenocarcinoma | Phase 2 | Completed | Ashwin Somasundaram | 18 | 2019-01-24 | 2023-12-19 |
| Evaluation of Pertuzumab-Trastuzumab and Taxane in the Standard Treatment of Metastatic Breast Cancer Breast Neoplasms, HER-2 Gene Amplification | Unknown | University Hospital, Brest | 63 | 2019-01-22 | 2019-06-07 | |
| Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1 HER2 DC1 Vaccine - Breast Cancer, HER2-positive Breast Cancer | Phase 2 | Terminated | H. Lee Moffitt Cancer Center and Research Institute | 16 | 2019-01-10 | 2022-04-25 |
| Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene A166 - HER2-positive Breast Cancer, HER2 Gene Mutation | Phase 1 / Phase 2 | Completed | Klus Pharma Inc. | 49 | 2018-07-16 | 2023-08-03 |
| A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach MM-111, Paclitaxel, Trastuzumab - HER-2 Gene Amplification, Esophagus Cancer | Phase 2 | Terminated | Merrimack Pharmaceuticals | 84 | 2013-01-01 | 2017-06-22 |
| A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer Cisplatin, Capecitabine, Trastuzumab and MM-111, Lapatinib +/- Trastuzumab and MM-111, Paclitaxel, Trastuzumab and MM-111 - HER-2 Gene Amplification | Phase 1 | Completed | Merrimack Pharmaceuticals | 100 | 2011-01-01 | 2015-12-16 |
Breast Neoplasms (5) · Stomach Neoplasms (4) · Neoplasm Metastasis (3) · Bile Duct Neoplasms (2) · Biliary Tract Neoplasms (2) · Carcinoma, Transitional Cell (2) · Cholangiocarcinoma (2) · Head and Neck Neoplasms (2) · Ovarian Neoplasms (2) · Pancreatic Neoplasms (2) · Prostatic Neoplasms (2) · Urinary Bladder Neoplasms (2) · Adenocarcinoma (1) · Adenocarcinoma Of Esophagus (1) · Breast Neoplasms, Male (1)
Neoplasms (9) · Neoplasms by Site (8) · Digestive System Diseases (6) · Digestive System Neoplasms (6) · Breast Diseases (5) · Carcinoma (5) · Gastrointestinal Diseases (5) · Gastrointestinal Neoplasms (5) · Neoplasms by Histologic Type (5) · Neoplasms, Glandular and Epithelial (5) · Skin Diseases (5) · Skin and Connective Tissue Diseases (5) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Stomach Diseases (4)
Trastuzumab (6) · MM-111 (2) · Paclitaxel (2) · pyrotinib (2) · Automobiles (1) · Capecitabine (1) · Cisplatin (1) · Docetaxel (1) · Fluorouracil (1) · Gemcitabine (1) · Irinotecan (1) · Lapatinib (1) · Leucovorin (1) · Oxaliplatin (1) · Receptors, Chimeric Antigen (1)
Merrimack Pharmaceuticals (2) · Ashwin Somasundaram (1) · Bellicum Pharmaceuticals (1) · Carisma Therapeutics Inc (1) · Changhoon Yoo (1) · Chinese Academy of Medical Sciences (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Jin-Hee Ahn (1) · Klus Pharma Inc. (1) · Morten Mau-Sørensen (1) · Orum Therapeutics USA, Inc. (1) · Tianjin Medical University Second Hospital (1) · University Hospital, Brest (1)
United States (8) · China (2) · Denmark (1) · France (1) · South Korea (1)
Akos Czibere, MD, PhD (1) · Ashwin Somasundaram, MD (1) · Changhoon Yoo, MD (1) · Haitao Wang (1) · Jeanett Wetzel (1) · Jordi Rodon Ahnert, MD, PhD (1) · Lene Baeksgaard, MD PhD (1) · Ricardo Costa, M.D. (1)